vpc23019

vpc23019 is an aryl amide-containing analog of sphingosine-1-phosphate (S1P) and acts as a competitive antagonist at the S1P1 (S1P receptor 1) and S1P3 (S1P receptor 3) receptors, with reported pKi values of 7.86 (S1P1) and 5.93 (S1P3)[1][10]. It is a small molecule organic phosphate used primarily as a research tool to study S1P receptor signaling[1][3]. Notably, vpc23019 has demonstrated inhibitory activity against S1P-induced migration of several cancer cell types, including thyroid cancer, ovarian cancer, and neural stem cells[3]. Its pharmacological profile is complex: while initially described as an antagonist, in some contexts and cell systems, vpc23019 can also act as a partial or full agonist at S1P3, S1P4, and S1P5 receptors, and these effects may vary depending on assay conditions and receptor conformation[2][4]. Its clinical utility has not been established, and it is not approved for therapeutic use[1].

Other names

2-Amino-N-(3-octylphenyl)-3-(phosphonooxy)-propanamide[(2R)-2-amino-3-(3-octylanilino)-3-oxopropyl] dihydrogen phosphate449173-19-7